Immunome Inc.

Biotechnology • Healthcare • Bothell, WA, United States • IMNM (NCM)

Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

425 939 7410 18702 North Creek Parkway, Bothell, WA 98011, United States Wikipedia

Stock Performance (90 Days)

Data through Dec 30, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Prediction: This Will Be the Top-Performing Streaming Stock in 2026 - The Motley Fool

The Motley Fool • Dec 30

Donald Trump Beats Joe Biden in the Stock Market Again - Hungarian Conservative

Hungarian Conservative • Dec 30

Immunome Announces Pricing of Public Offering of Common Stock - Business Wire

Business Wire • Dec 16

GM's record stock performance beats Tesla, Ford and other automakers in 2025 - CNBC

CNBC • Dec 29

The 'Knockout' Hit That Sent This Top 3% Biotech Stock Flying - Investor's Business Daily

Investor's Business Daily • Dec 15

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Immunome Inc. had layoffs?

No layoff events have been recorded for Immunome Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Immunome Inc. have?

Immunome Inc. has approximately 168 employees.

What industry is Immunome Inc. in?

Immunome Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Immunome Inc. a publicly traded company?

Yes, Immunome Inc. is publicly traded under the ticker symbol IMNM on the NCM. The company has a market capitalization of approximately $2.35 billion.

Where is Immunome Inc. headquartered?

Immunome Inc. is headquartered in Bothell, WA, United States at 18702 North Creek Parkway, Bothell, WA 98011, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.